We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 711% below its sector, cheaper than its peers on earnings.
Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300463.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
